Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Shopify Inc. (SHOP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Shopify Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Shopify Inc. trades at $125.85 (market cap $159.01B). The key difference: Shopify Inc. is far larger — about 4× Alnylam Pharmaceuticals, Inc.'s market cap, and Shopify Inc. is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SHOP | |
|---|---|---|
Market Cap | $39.89B | $159.01B |
Sector | Health | Technology |
52-Week High | $491.22 | $179.01 |
52-Week Low | $278.09 | $95.40 |
Enterprise Value | $38.15B | $153.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Shopify (SHOP) trades at $122.54, down 0.51% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $149.18. Revenue grew to $11.56 billion in 2025, with net income of $1.23 billion, though valuation ratios like P/E of 120.14 remain elevated. Recent news highlights Bank of America reinstating coverage with a Buy rating and $150 target, citing AI-driven commerce growth potential.
The stock offers upside potential from strong revenue growth and AI adoption, but risks include high valuation sensitivity and tech sector volatility. Analyst sentiment is overwhelmingly positive with 65% Buy ratings, but investors should monitor execution against earnings expectations, especially with Q2 2026 results due August 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Shopify Inc.
Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →
